Adjuvant therapy for renal cell carcinoma
作者机构：Department of OncologyUniversity College London Cancer InstituteLondon WC1E 6DDUK St Luke’s Cancer CentreRoyal Surrey County HospitalGuildford GU27XXUK
出 版 物：《Journal of Cancer Metastasis and Treatment》 (癌症转移与治疗（英文版）)
年 卷 期：2021年第7卷第1期
页 面：686-694页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Localized renal cell carcinoma adjuvant immunotherapy tyrosine kinase inhibitors prognosis clinical trials predictive model risk stratification
摘 要：Recent advances in the treatment of metastatic renal cell carcinoma expose a gap in the treatment of less advanced,localized *** kinase inhibitors,which revolutionized the treatment of metastatic disease,have not provided a similar survival benefit in the adjuvant setting and currently only sunitinib is approved by the Food and Drug Administration for adjuvant treatment in patients with high-risk of recurrence based on S-TRAC disease-free survival *** advent of immune checkpoint inhibitors has offered a fresh hope in the field of adjuvant treatment after encouraging results are seen with combination of immune checkpoint inhibitors as well as with targeted therapy in the metastatic *** studies are investigating these combinations in the adjuvant setting,and it is hoped that they will bring about a better outcome for a largely unmet need in kidney cancer treatment.
维普期刊数据库